"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut ...

Ionis already has experience in the ASO space, with its first-generation therapy Tegsedi (inotersen) also approved for ATTRv-PN. However, Tegsedi requires weekly subcutaneous injections and comes with ...

Prothena Corporation focuses on neurodegenerative diseases with a diverse pipeline, including Birtamimab for AL amyloidosis, which is in a phase 3 trial. Despite past trial failures, Birtamimab ...

AZ paid $200 million upfront in 2021 to partner eplontersen, Ionis’ second drug for ATTR after Tegsedi (inotersen), which has lagged in the ATTR polyneuropathy market behind Alnylam’s Onpattro ...

The FDA has approved Ionis Pharmaceuticals’ RNA silencing drug Tegsedi (inotersen) for nerve damage caused by a rare disease. This is the second drug to hit the market this year for ...